FDA grants breakthrough therapy designation to pemvidutide for MASH
A faster-review designation for an investigational MASH drug points to a possible new option for a progressive liver disease that can lead to cirrhosis, though Phase 3 testing has not begun.
The FDA has granted Breakthrough Therapy Designation to pemvidutide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), developer Altimmune announced on January 5, 2026 [1]. Pemvidutide is an investigational, balanced 1:1 glucagon/GLP-1 dual receptor agonist and has not been approved for any use [1].
Breakthrough Therapy Designation is meant to speed up development and review of medicines intended to treat a serious or life-threatening condition that have shown preliminary clinical evidence of the potential for substantial improvement over available therapies on a clinically significant endpoint [1].
The designation was granted based on 24-week data from the IMPACT Phase 2b trial showing statistically significant MASH resolution without worsening of fibrosis, along with early and substantial improvements in liver fat and in non-invasive tests of fibrosis and liver inflammation [1]. The announcement does not report how large those treatment effects were, how many patients were involved, or how the results compared with placebo at 24 weeks beyond the description of statistical significance; those figures have not been disclosed here [1].
In December 2025, the company reported 48-week topline IMPACT data showing that continued pemvidutide treatment produced statistically significant improvements versus placebo in key non-invasive tests, including Enhanced Liver Fibrosis (ELF) and Liver Stiffness Measurement (LSM), with additional reductions from week 24 at both dose levels [1]. At 48 weeks, patients receiving the 1.8 mg dose lost further weight with no evidence of plateauing, and the drug kept the tolerability profile seen at 24 weeks, including a lower rate of discontinuation due to adverse events than placebo [1].
Altimmune said it completed an end-of-phase 2 meeting with the FDA in December 2025, and that the final meeting minutes confirmed agreement on parameters for a registrational Phase 3 trial in MASH patients with moderate to advanced liver fibrosis [1]. The company plans a Phase 3 trial testing multiple pemvidutide doses over a 52-week treatment period, using biopsy-based endpoints intended to support a possible accelerated approval, and the AIM-MASH AI Assist tool, which the release describes as the first AI pathology tool qualified by the FDA for use in MASH clinical trials [1]. Altimmune said it will also seek scientific advice from European regulators and will consider that input when finalizing the Phase 3 protocol [1]. A start date for the Phase 3 trial has not been disclosed [1].
MASH is a progressive liver disease marked by fat accumulation, inflammation and fibrosis in the liver. Without treatment it can progress to cirrhosis, liver failure or liver cancer, and it is one of the most common reasons for liver transplantation in the United States [1]. The release states that currently approved treatments may not fully address both the metabolic drivers and the fibrosis that pose long-term risk for patients with MASH [1].
"The FDA's Breakthrough Therapy Designation for pemvidutide in MASH reinforces the promise of its clinical profile and potential to address significant unmet needs in this serious, progressive liver disease," said Jerry Durso, Altimmune's president and chief executive officer [1].
Pemvidutide is also in development for alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). It holds FDA Fast Track designations for MASH and AUD in addition to the MASH breakthrough designation, and Phase 2 trials in AUD (RECLAIM) and ALD (RESTORE) began in May 2025 and July 2025 and are ongoing [1].
Why it matters for patients
A breakthrough designation is not an approval, and it is not proof that a drug works. It signals that the FDA sees early evidence promising enough to justify a faster development path and closer agency involvement [1]. For people with MASH, which the release describes as a serious, progressive disease with treatment options that may not address both metabolic drivers and fibrosis, the designation points to a possible additional option in the pipeline. It does not mean pemvidutide is available now, and no timeline for a potential approval has been disclosed [1].
Pemvidutide is an investigational drug rather than an approved one, and Altimmune describes it as a balanced 1:1 glucagon/GLP-1 dual receptor agonist, a mechanism distinct from the GLP-1 medicines currently on the market [1]. Its 48-week results so far come from non-invasive tests of liver fibrosis and stiffness, not from biopsy findings at that time point; the company describes the week-24 biopsy-based result as resolution of MASH without worsening of fibrosis [1]. Whether those early signals hold up in a larger Phase 3 trial has not been established [1].
Because pemvidutide is still in development, it is not covered by insurance, not available by prescription, and its price is unknown; nothing about cost or coverage has been reported [1].
What happens next
Altimmune plans a Phase 3 trial in MASH patients with moderate to advanced liver fibrosis, testing multiple doses over 52 weeks with biopsy-based endpoints intended to support a possible accelerated approval [1]. No start date has been announced [1]. The company will seek scientific advice from European regulators before finalizing the protocol [1]. Two Phase 2 trials continue: RECLAIM in alcohol use disorder, which began in May 2025, and RESTORE in alcohol-associated liver disease, which began in July 2025 [1]. Results and timing for those trials, and for the Phase 3 MASH trial, have not been disclosed [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.